Ethyl 2-bromomethylbenzoate triphenylphosphonium salt | 59636-00-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Ethyl 2-bromomethylbenzoate triphenylphosphonium salt
• 英文别名: Triphenyl phosphonium salt of the ethyl ester of 2-bromomethylbenzoic acid；[2-(ethoxycarbonyl)benzyl]triphenylphosphonium bromide；(o-ethoxycarbonylbenzyl)triphenylphosphonium bromide；ethyl 2-[(triphenylphosphino)methyl]benzoate bromide；2-Ethoxycarbonylbenzyltriphenylphosphonium bromide；(2-ethoxycarbonylphenyl)methyl-triphenylphosphanium;bromide
• CAS: 59636-00-9
• 化学式: Br*C₂₈H₂₆O₂P
• 分子量: 505.391
• InChiKey: IISOIQHTJLMMLZ-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  2.36
• 重原子数：
  32
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Ethyl 2-bromomethylbenzoate triphenylphosphonium salt 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 邻甲基苯甲酸乙酯
  参考文献：
  名称：

  Teitei, Tsutomu, Agricultural and Biological Chemistry, 1981, vol. 45, # 7, p. 1669 - 1674

  摘要：

  DOI：
• 作为产物：
  描述：

  邻甲基苯甲酸乙酯 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 作用下， 以 四氯化碳 、 甲苯 为溶剂， 生成 Ethyl 2-bromomethylbenzoate triphenylphosphonium salt
  参考文献：
  名称：

  Wittig反应和串联还原环化-内酰胺化合成6H-Isoindolo[2,1-a]indol-6-ones

  摘要：

  以邻硝基苯甲醛为原料，开发了一种便捷高效的两步法制备 6H-异吲哚并[2,1-a]吲哚-6-酮。该方法涉及 Wittig 反应，然后是串联还原环化 - 内酰胺化。已经制备了一系列在吲哚核上结合不同取代基的异吲哚吲哚酮。

  DOI：

  10.1002/ejoc.201300047

文献信息

• Thiazolylbenzofuran derivatives and pharmaceutical composition
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US05296495A1

  公开（公告）日：1994-03-22

  Compounds of the formula: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, A, X and Y are as defined and pharmaceutically acceptable salts thereof; which have activities as leukotriene and Slow Reacting Substance of Anaphalaxis (SRS-a) antagonists or inhibitors, to processes for preparation thereof, to a pharmaceutical composition comprising the same, and to methods of using the same therapeutically in the prevention and/or treatment of allergy or inflamation in human beings or animals.

  式中R.sup.1、R.sup.2、R.sup.3、R.sup.4、A、X和Y的化合物：##STR1##及其药学上可接受的盐；具有作为白三烯和缓激反应物质（SRS-a）拮抗剂或抑制剂的活性，其制备方法，包括其的制药组合物，以及在人类或动物中在预防和/或治疗过敏或炎症方面的治疗方法。
• Microbicidal nitrofuryl compounds
  申请人：Byk Gulden Lomberg Chemische Fabrik GmbH

  公开号：US04051253A1

  公开（公告）日：1977-09-27

  2-[(O-ALKYLAROYLHYDRAZONO)PROPEN-1-YL]-5-NITROFURANS [1] ARE PREPARED BY CONDENSING 3-(5-NITRO-2-FURYL)ACRYLALDEHYDE [2] WITH AN O-ALKYLAROYL HYDRAZIDE [3]. Compounds [1] are bactericides, protozoacides and fungicides and are administrable to animals in therapeutically-acceptable compositions.

  2-[(O-烷基芳酰肼基)丙烯酰基]-5-硝基呋喃[1]是通过将3-(5-硝基-2-呋喃基)丙烯醛[2]与O-烷基芳酰肼[3]缩合制备而成。化合物[1]是杀菌剂、原虫剂和杀真菌剂，并可在治疗可接受的组合物中给动物使用。
• A Convenient Synthesis of Methyl 1-Alkoxy-3-perfluoroalkyl-2-naphthoates
  作者：Weiyu Ding、Jiaqi Pu、Chunming Zhang

  DOI：10.1055/s-1992-26182

  日期：——

  Methyl 1-alkoxy-3-perfluoroalkyl-2-naphthoates 5 were synthesized by heating appropriately substituted 2-triphenylphosphoranylidene-2-butenoates 3 in xylenes at 250°C in a sealed tube. Compounds 3 were obtained via an intramolecular Wittig reaction of 2-alkoxycarbonylbenzyltriphenylphosphonium bromide (1) with methyl 2-perfluoroalkynoates 2 in the presence of potassium carbonate.

  1- 烷氧基-3-全氟烷基-2-萘甲酸甲酯 5 是在密封管中于 250°C 下在二甲苯中加热适当取代的 2-三苯基膦亚基-2-丁烯酸甲酯 3 而合成的。化合物 3 是通过 2-烷氧基羰基苄基三苯基溴化膦 (1) 与 2-全氟炔酸甲酯 2 在碳酸钾存在下发生分子内 Wittig 反应而得到的。
• Organic compounds
  申请人：Novartis AG

  公开号：US08084448B2

  公开（公告）日：2011-12-27

  Compounds of the formula are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer, osteoporosis, musculoskeletal, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

  公式为的化合物是蛋白酪氨酸磷酸酶（PTPase）的抑制剂，因此可用于治疗PTPase活性介导的疾病。本发明的化合物也可用作其他酶的抑制剂，这些酶具有磷酸酪氨酸结合区域，如SH2结构域。因此，公式（I）的化合物可用于预防和/或治疗与肥胖、葡萄糖耐受性、糖尿病、高血压和大、小血管缺血性疾病相关的胰岛素抵抗，以及伴随2型糖尿病的情况，包括高脂血症、高三酰甘油血症、动脉粥样硬化、血管再狭窄、肠易激综合征、胰腺炎、脂肪细胞肿瘤和脂肪肉瘤、脂质代谢异常和其他表现为胰岛素抵抗的疾病。此外，本发明的化合物可用于治疗和/或预防癌症、骨质疏松症、肌肉骨骼、神经退行性和传染性疾病，以及涉及炎症和免疫系统的疾病。
• ORGANIC COMPOUNDS
  申请人：Neubert Alan

  公开号：US20090181928A1

  公开（公告）日：2009-07-16

  Compounds of the formula are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer, osteoporosis, musculoskeletal, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

  公式的化合物是蛋白酪氨酸磷酸酶（PTPases）的抑制剂，因此可用于治疗由PTPase活性介导的疾病。本发明的化合物也可用作其他酶的抑制剂，这些酶具有磷酸酪氨酸结合区域，如SH2结构域。因此，公式（I）的化合物可用于预防和/或治疗与肥胖、葡萄糖不耐受、糖尿病、高血压以及大、小血管缺血性疾病有关的胰岛素抵抗。这些疾病包括高脂血症、高三酰甘油血症、动脉粥样硬化、血管再狭窄、肠易激综合征、胰腺炎、脂肪细胞肿瘤和脂肪肉瘤等癌症，以及其他显示胰岛素抵抗的疾病。此外，本发明的化合物可用于治疗和/或预防癌症、骨质疏松症、肌肉骨骼、神经退行性和传染性疾病，以及涉及炎症和免疫系统的疾病。